MIS416

MIS416 is a novel immunomodulator developed by Innate Immunotherapeutics Limited, a biotechnology company based in New Zealand. It is designed to stimulate the innate immune system, the body's first line of defense against infection and disease.

Mechanism of Action[edit | edit source]

MIS416 works by targeting and activating monocytes and dendritic cells, key components of the innate immune system. These cells then produce a range of cytokines and chemokines, signaling proteins that modulate the immune response. This results in a broad, non-specific immune response that can potentially target a range of diseases.

Clinical Trials[edit | edit source]

MIS416 has been tested in several clinical trials, primarily for the treatment of secondary progressive multiple sclerosis (SPMS). In these trials, MIS416 showed potential benefits in reducing the severity and progression of SPMS. However, further research is needed to confirm these findings and determine the optimal dosage and treatment regimen.

Potential Applications[edit | edit source]

In addition to SPMS, MIS416 may have potential applications in other diseases that involve the immune system. These include other forms of multiple sclerosis, as well as autoimmune diseases, cancer, and infectious diseases. However, these potential applications are still in the early stages of research and development.

Safety and Side Effects[edit | edit source]

Like all drugs, MIS416 has potential side effects. These can include flu-like symptoms, such as fever and chills, as well as injection site reactions. However, these side effects are generally mild and temporary. The safety of MIS416 is still being evaluated in ongoing clinical trials.